Manufacturer of Controlled Substances; Notice of Registration, 5829-5830 [2011-2295]
Download as PDF
<![CDATA[
5829
Federal Register / Vol. 76, No. 22 / Wednesday, February 2, 2011 / Notices
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2284 Filed 2–1–11; 8:45 am]
[FR Doc. 2011–2288 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 25, 2010,
AMRI Rensselaer, Inc., 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
srobinson on DSKHWCL6B1PROD with NOTICES
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Meperidine (9230) ........................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
16:00 Feb 01, 2011
Jkt 223001
Schedule
Drug
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 4, 2011.
VerDate Mar<15>2010
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 24,
2010, Sigma Aldrich Research
Biochemicals, Inc., 1–3 Strathmore
Road, Natick, Massachusetts 01760–
2447, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following classes of
controlled substances:
Cathinone (1235) ...........................
Methcathinone (1237) ....................
Aminorex (1585) .............................
Alpha-ethyltryptamine (7249) .........
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .......
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine (7392).
2,5-Dimethoxyamphetamine (7396)
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493) ..
Heroin (9200) .................................
Normorphine (9313) .......................
Amphetamine (1100) ......................
Methamphetamine (1105) ..............
Nabilone (7379) ..............................
1-Phenylcyclohexylamine (7460) ...
Phencyclidine (7471) ......................
Cocaine (9041) ...............................
Codeine (9050) ..............................
Diprenorphine (9058) .....................
Ecgonine (9180) .............................
Levomethorphan (9210) .................
Levorphanol (9220) ........................
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
Drug
Meperidine (9230) ..........................
Metazocine (9240) .........................
Methadone (9250) ..........................
Morphine (9300) .............................
Thebaine (9333) .............................
Levo-alphacetylmethadol (9648) ....
Remifentanil (9739) ........................
Carfentanil (9743) ..........................
Fentanyl (9801) ..............................
Schedule
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 4, 2011.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2237 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Registration
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
By Notice dated August 3, 2010, and
published in the Federal Register on
September 1, 2010, 75 FR 53719,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambridge Isotope Lab to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
E:\FR\FM\02FEN1.SGM
02FEN1
5830
Federal Register / Vol. 76, No. 22 / Wednesday, February 2, 2011 / Notices
investigated Cambridge Isotope Lab to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2295 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 3, 2010, and
published in the Federal Register on
September 1, 2010, (75 FR 53720),
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
Drug
Schedule
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Phenazocine (9715) .....................
Fentanyl (9801) ............................
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
American Radiolabeled Chemicals, Inc.
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated American
Radiolabeled Chemicals Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2294 Filed 2–1–11; 8:45 am]
srobinson on DSKHWCL6B1PROD with NOTICES
BILLING CODE 4410–09–P
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Dimethyltryptamine (7435) ...........
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Metazocine (9240) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
VerDate Mar<15>2010
16:00 Feb 01, 2011
I
I
I
I
I
I
DEPARTMENT OF JUSTICE
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
By Notice dated August 2, 2010, and
published in the Federal Register on
September 1, 2010, 75 FR 53720, Cody
Laboratories, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
II
Jkt 223001
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Drug
Schedule
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
I
II
II
II
II
Drug
Secobarbital (2315) ......................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Cody
Laboratories to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Cody
Laboratories to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–2291 Filed 2–1–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Federal Bureau of Investigation
[Docket No. FBI 150]
FBI Records Management Division;
National Name Check Program
Section; New User Fees Schedule
Federal Bureau of Investigation
(FBI), Justice.
ACTION: Notice.
AGENCY:
Pursuant to 28 CFR
20.31(e)(3), this notice establishes a new
SUMMARY:
E:\FR\FM\02FEN1.SGM
02FEN1
]]>Agencies
[Federal Register Volume 76, Number 22 (Wednesday, February 2, 2011)]
[Notices]
[Pages 5829-5830]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-2295]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated August 3, 2010, and published in the Federal
Register on September 1, 2010, 75 FR 53719, Cambridge Isotope Lab, 50
Frontage Road, Andover, Massachusetts 01810, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of Morphine (9300), a basic class of controlled
substance listed in schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambridge Isotope Lab to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has
[[Page 5830]]
investigated Cambridge Isotope Lab to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33,
the above named company is granted registration as a bulk manufacturer
of the basic class of controlled substance listed.
Dated: January 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-2295 Filed 2-1-11; 8:45 am]
BILLING CODE 4410-09-P
